Entries by Maud Vanderthommen

Publication of Transparency Notifications Received from Goldman Sachs

Liege, Belgium, 29 April 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that […]

Mithra Announces the Extension of the Capital Commitment Agreement with LDA Capital by Two Years and the Increase of the Commitment by EUR 25 million

Liege, Belgium, 18 April 2022 – 7:30 CEST – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (“Mithra” or the “Company”), a company dedicated to Women’s Health, today announces the extension of the capital commitment agreement with LDA Capital Limited (“LDA Capital“) for a period of two additional years, as well as the increase of the commitment […]

Mithra Announces Positive Top-Line Results from Donesta® Phase 3 Studies in Menopausal Women

Liege, Belgium, 14 January 2022 – 07:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces positive efficacy top-line results from Donesta® Phase 3 pivotal “E4 Comfort” clinical trials for the treatment of Vasomotor Symptoms (VMS) in postmenopausal women. Donesta® is Mithra’s next generation orally-administrated estetrol (E4)-based hormone therapy product […]

Liege, Belgium, November 29, 2021 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the holding of its Investor Day today at its R&D and production center, the Mithra CDMO in Flémalle, Belgium. As of 9:00 am CET, all presentations can be simultaneously followed by webcast on the […]

Information on the Total Number of Voting Rights Following the Completion of the LDA Capital Increase

Liege, Belgium, 10 November 2021 – 17:45 CET – In accordance with article 15 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Mithra Pharmaceuticals SA (the “Company” or “Mithra”) announces the below […]

Mithra Announces Topline Results for COVID-19 Phase II Study

Liege, Belgium, 24 September 2021 – 7:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces topline results of the Coronesta Phase II study, which aimed to assess the safety and efficacy of estetrol (E4) for the treatment of patients who were hospitalized with moderate COVID-19. E4 is a native […]